Sort
10,766 grants matching “checkpoint inhibitor”
POTENTIATION OF TAXANE ACTIVITY BY MEK/MAPK INHIBITORS
$168,863Virginia Commonwealth University · R01 · FY2003 · CA
Immunologic Approaches to Ovarian Cancer
$168,500Paul J Sabbatini · Sloan-Kettering Inst Can Research · P01 · FY2018 · CA
Novel CCR2 PET for Pancreatic Cancer Imaging and Prediction of Response to Standard and CCR2-Targeted Therapy
$168,482Farrokh Dehdashti · Washington University · R01 · FY2023 · CA
Effect of SARS-CoV-2 on clinical course and NK cells in patients receiving immunotherapy
$168,429Nina Bhardwaj · Icahn School Of Medicine At Mount Sinai · R01 · FY2020 · CA
Drug combination nanoparticles for advanced treatment of metastatic TNBC
$168,413Qingxin Mu · University Of Washington · R21 · FY2024 · CA
Protection of kidney from autoimmunity by modulating co-stimlatory signaling
$168,360Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2022 · DK
Protection of kidney from autoimmunity by modulating co-stimlatory signaling
$168,360Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2023 · DK
Protection of kidney from autoimmunity by modulating co-stimlatory signaling
$168,360Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2021 · DK
Protection of kidney from autoimmunity by modulating co-stimlatory signaling
$168,360Naoka Murakami · Brigham And Women'S Hospital · K08 · FY2020 · DK
Clinical protocols for the treatment of gastrointestinal cancer
$168,145Tim Greten · Division Of Basic Sciences - Nci · ZIA · FY2015 · CA
Advancing WRN as a synthetic lethal target for microsatellite unstable cancers
$168,125Edmond Chan · Columbia University Health Sciences · K08 · FY2025 · CA
TRANSPOSASE PROTEIN METNASE IN LEUKEMIC DECATENATION
$168,000Robert A Hromas · University Of New Mexico · R01 · FY2009 · HL
RNA editing in islet function and inflammation
$167,927Alvin Carter Powers · Vanderbilt University Medical Center · R01 · FY2025 · DK
Targeting a novel glyco-immune checkpoint for cancer immunotherapy
$167,771Michael Chiorazzi · Yale University · R03 · FY2025 · CA
Role of Polo-like kinase (Plk-1) in Hepatitis B Virus-mediated Hepatocellular Car
$167,750Ourania M. Andrisani · Purdue University · R21 · FY2010 · CA
Project 3 - Genome-Guided Therapeutic Vulnerabilities in Esophageal Cancer
$167,612Adam Joel Bass · Columbia University Health Sciences · P01 · FY2020 · CA
Interaction of substrates and inhibitors with tousled-like kinase 2
$167,500Benjamin E Turk · Yale University · R03 · FY2019 · TR
Autoimmunity to Protein Modifications in Checkpoint Inhibitor Induced and Spontaneous T1D
$167,500Mark J. Mamula · Yale University · R01 · FY2018 · DK
(PQ11) Reversing exosome-mediated immune suppression - a novel strategy for cancer therapy
$167,475Theresa L. Whiteside · University Of Pittsburgh At Pittsburgh · R21 · FY2016 · CA
Overcoming resistance to cancer immunotherapy by targeting MDSC-derived adenosine
$167,475Kavitha Yaddanapudi · University Of Louisville · R21 · FY2021 · CA
Core 2: Glioblastoma Biorepository Core
$167,412Keith L Ligon · Brigham And Women'S Hospital · P01 · FY2019 · CA
Project 1: Elucidating the role of AAA ATPase TRIP13 in prostate cancer
$167,362Sooryanarayana Varambally · University Of Alabama At Birmingham · U54 · FY2023 · CA
Project 1: Elucidating the role of AAA ATPase TRIP13 in prostate cancer
$167,360Sooryanarayana Varambally · University Of Alabama At Birmingham · U54 · FY2022 · CA
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
$167,292Gerlinde Wernig · Stanford University · K08 · FY2018 · HL
Immune Checkpoint Inhibitors as Antifibrotic Therapy for Idiopathic Pulmonary Fibrosis
$167,292Gerlinde Wernig · Stanford University · K08 · FY2019 · HL